Seer, Inc.

SEER Healthcare Biotechnology

Seer, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $16.6 million, up 17.0% from fiscal 2024. In the quarter to June 2026, revenue fell 23.4%, EPS grew 6.06% and free cash flow grew 36.7%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

2.03 0.01 −0.49%
Market cap
$113.0M
P/E
0.0×
Fwd P/E
−1.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.55
Beneish M
−2.98
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
7.46 6.34 6.20 6.44
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(16.15) (9.73) (6.09) (9.57)
P/B ratio
0.45 0.41 0.39 0.41
EV/Sales
(4.70) (4.87) (4.79) (4.31)
EV/EBITDA
1.01 1.14 1.07 0.96
EV/FCF
1.71 1.77 1.47 1.39
Current Ratio
14.25 12.84 17.73 14.74
Net Debt/EBITDA
11.55 11.47 11.14 9.78
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
(62.67%) (69.95%) (73.81%) (73.49%)
Free Cash Flow Yield
(36.89%) (43.37%) (52.65%) (48.03%)
Free Cash Flow per Share
(0.14) (0.19) (0.28) (0.17)
Book value per Share
4.83 4.51 4.31 4.09
Free Cash Flow
(7.61) (11.10) (15.70) (9.57)
EV/EBIT
0.92 1.04 0.97 0.87
Other line items

Show all line items

Columns are period end dates